Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
17:06 | Israel stocks lower at close of trade; TA 35 down 1.14% | ||
15:18 | DS-3939 shows promising results in early trials against solid tumors | ||
15:06 | Raludotatug deruxtecan shows 50.5% response rate in ovarian cancer trial | ||
14:54 | Saudi Arabia stocks lower at close of trade; Tadawul All Share down 0.05% | ||
14:18 | RAPT Therapeutics to report phase 2 trial data for urticaria drug | ||
12:06 | US semis & hardware: Two years into the AI boom - who has benefited most? | ||
11:18 | 'Best houses in a tough neighbourhood,' Morgan Stanley upbeat on UK stocks | ||
11:18 | 5 big analyst AI moves: Nvidia, AMD upgraded; ASML seen on €1,000 path | ||
10:30 | Pancreatic cancer drug shows 41% response rate in clinical trial | ||
10:18 | Can MSCI India weight converge with China's? | ||
10:18 | These analysts say the AI spending boom is "not too big." Here's why. | ||
Sa | Russia stocks lower at close of trade; MOEX Russia Index unchanged | ||
Sa | Kelun-Biotech's breast cancer drug shows promising phase 3 results | ||
Sa | ENHERTU shows 92% invasive disease-free survival rate at three years in breast cancer trial | ||
Sa | ESMO 2025: enhertu shows highest pCR rate in HER2+ early breast cancer | ||
Sa | Is it really a "Golden Age of Construction"? | ||
Sa | Could weight-loss drugs hit restaurant sales? UBS weighs in. | ||
Sa | Federal leverage over Fannie, Freddie could shape Trump's housing push | ||
Sa | How OpenAI deal can make Walmart a trillion dollar market cap company | ||
Sa | Will Q3 earnings rescue European equities as 2026 looms? | ||
Sa | Pension reform can be the catalyst to transform European markets - Morgan Stanley | ||
Sa | Gedatolisib shows strong results in breast cancer trial | ||
Sa | Celcuity reports positive Phase 1 data for prostate cancer therapy | ||
Sa | Celcuity completes enrollment for PIK3CA mutant cohort in phase 3 trial | ||
Sa | Is Meta facing its Alphabet-ChatGPT moment? |